AHA Late-Breaker ARTESiA: Apixaban for t...

Continuous cardiac monitoring detects brief, asymptomatic, heart rhythm abnormalities in one-third of older individuals and these symptoms are associated with an increased risk of stroke. 

The ARTESiA trial clearly demonstrates that use of the blood thinner apixaban reduces patient risk of stroke compared to treatment with aspirin, but is associated with an increased risk of bleeding. 

In this interview, Jeff S. Healey, MD, and Thomas F. Deering MD, FACC, discuss AHA Late-Breaker: Apixaban for the Prevention of Stroke in Patients With Subclinical Atrial Fibrillation. 

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL